Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Lung Cancer

  Free Subscription


30.06.2025

1 Am J Surg
1 Ann Oncol
1 Ann Surg Oncol
4 Ann Thorac Surg
6 Anticancer Res
1 Cancer
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
3 Chest
2 Clin Cancer Res
2 Clin Lung Cancer
1 Eur J Cancer
4 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
1 J Thorac Cardiovasc Surg
2 JAMA Oncol
7 Lung Cancer
2 Mol Carcinog
3 Oncologist
2 PLoS One
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Surg

  1. WILLIAMS JE, Jacobson-Davies F, Jacobs RC, Chang AC, et al
    Association of social vulnerability on time-to-treatment for patients with non-small cell lung cancer.
    Am J Surg. 2025;247:116481.
    PubMed         Abstract available


    Ann Oncol

  2. RICCIUTI B, Scalera S, Wang X, Elkrief A, et al
    DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer.
    Ann Oncol. 2025 Jun 18:S0923-7534(25)00804-X. doi: 10.1016/j.annonc.2025.
    PubMed         Abstract available


    Ann Surg Oncol

  3. LI P, Huang K, Wu Q, Che G, et al
    Influence of Cycles of Neoadjuvant Chemoimmunotherapy on Treatment Response in Stage IIIA-N2IIIB Non-small Cell Lung Cancer: Experience from a Large-Volume Center.
    Ann Surg Oncol. 2025 Jun 24. doi: 10.1245/s10434-025-17598.
    PubMed         Abstract available


    Ann Thorac Surg

  4. HURR R, Potter AL, Jeffrey Yang CF
    Improving Lung Cancer Screening Uptake Takes a Village: The Power of Partnering with High Catchment Hospital Departments.
    Ann Thorac Surg. 2025 Jun 18:S0003-4975(25)00532.
    PubMed        

  5. RYUKO T, Okazaki M, Mitsuhashi T, Suzawa K, et al
    Comparable Clinical Outcomes Between Segmentectomy and Lobectomy for NSCLC With Unsuspected N1/N2: A Multicenter Real-World Data Study.
    Ann Thorac Surg. 2025;120:87-98.
    PubMed         Abstract available

  6. WEN J, Chen T, Li Y, Dong Y, et al
    Comparison of Short- and Long-term Outcomes in Patients Undergoing Sleeve Lobectomy With or Without Buttressing the Bronchial Anastomosis.
    Ann Thorac Surg. 2025;120:100-107.
    PubMed         Abstract available

  7. OPITZ I, Lauk O, Werner R, Matter A, et al
    Characteristics of Long-term Survivors With Malignant Pleural Mesothelioma.
    Ann Thorac Surg. 2025;120:108-116.
    PubMed         Abstract available


    Anticancer Res

  8. LI JM, Yang KT, Wu CP
    Physalin F Inhibits Cell Viability and Induces Apoptosis in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2025;45:3031-3044.
    PubMed         Abstract available

  9. SOMBOONVORAVONG W, Petsri K, Racha S, Sriratanasak N, et al
    Artogomezianone Inhibits EGFR and Promotes Apoptosis in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2025;45:2833-2845.
    PubMed         Abstract available

  10. AIDA R, Okano K, Nakata K, Hagiwara H, et al
    Apigenin-induced Apoptosis in Lung Adenocarcinoma A549 Cells: Involvement in IFNA2, TNF, and SPON2 With Different Time Points.
    Anticancer Res. 2025;45:2781-2790.
    PubMed         Abstract available

  11. PHANSOM N, Ei ZZ, Innets B, Wattanathana W, et al
    Development of a Benzoxazine-derived Inhibitor Targeting Epithelial-to-Mesenchymal Transition in Lung Cancer.
    Anticancer Res. 2025;45:2807-2815.
    PubMed         Abstract available

  12. KIM HL, Park J, Kim HI, Boo M, et al
    Integrating Network Pharmacology and Optimization of Preparation Methods to Enhance the Anticancer Effect of Cordyceps militaris on Lung Cancer.
    Anticancer Res. 2025;45:2963-2984.
    PubMed         Abstract available

  13. INNETS B, Racha S, Ei ZZ, Sriratanasak N, et al
    Resveratrol Derivatives Inhibit Pro-survival Akt Signaling Pathway in Lung Cancer.
    Anticancer Res. 2025;45:3021-3029.
    PubMed         Abstract available


    Cancer

  14. BROWN LM, Wilkins SG, Bansal VV, Su DG, et al
    Consensus guideline for the management of peritoneal mesothelioma.
    Cancer. 2025;131:e35868.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  15. BERKMAN AM, Tran M, Thompson LK, Lerman C, et al
    SECONDARY LUNG CANCER AMONG SURVIVORS OF ADOLESCENT AND YOUNG ADULT CANCER: A POPULATION-BASED STUDY.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available


    Cancer Lett

  16. HUANG Y, Song J, Chen J, Li F, et al
    The significance of protein N-glycosylation in the pathogenesis of lung cancer and its clinical implications.
    Cancer Lett. 2025 Jun 25:217849. doi: 10.1016/j.canlet.2025.217849.
    PubMed         Abstract available


    Chest

  17. XIE Y, Zhang Y, Zhang P, Li Y, et al
    Timing of screening benefit for lung cancer with low-dose computed tomography.
    Chest. 2025 Jun 18:S0012-3692(25)00707-X. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available

  18. BARTA JA, Arenberg D, Backhus L, Detterbeck F, et al
    Components Necessary for High-Quality Lung Cancer Screening: A 10-Year Update.
    Chest. 2025 Jun 17:S0012-3692(25)00700-7. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available

  19. HOWINGTON J, Souter LH, Arenberg D, Blasberg J, et al
    Management of Patients with Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline.
    Chest. 2025 Jun 23:S0012-3692(25)00737-8. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available


    Clin Cancer Res

  20. DAVAR D, Eroglu Z, Milhem M, Becerra C, et al
    Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.
    Clin Cancer Res. 2025 Jun 24:OF1-OF9. doi: 10.1158/1078-0432.CCR-25-0806.
    PubMed         Abstract available

  21. GAY CM, Owonikoko TK, Byers LA, Choudhury NJ, et al
    Multidimensional Analysis of B7 homolog 3 (B7-H3) RNA Expression in Small-cell Lung Cancer Molecular Subtypes.
    Clin Cancer Res. 2025 Jun 24. doi: 10.1158/1078-0432.CCR-24-3981.
    PubMed         Abstract available


    Clin Lung Cancer

  22. LIN JX, Zhou Q, Yan HH, Liu AW, et al
    A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203).
    Clin Lung Cancer. 2025 May 28:S1525-7304(25)00127.
    PubMed         Abstract available

  23. KOSTER KL, Yohasenan S, Pakmak AS, Mark M, et al
    Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter Study.
    Clin Lung Cancer. 2025 May 29:S1525-7304(25)00124.
    PubMed         Abstract available


    Eur J Cancer

  24. O'REILLY D, O'Grady A, Hayes C, Piggott L, et al
    Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study.
    Eur J Cancer. 2025;225:115582.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  25. ZHANG SC, Kehayias CE, Guthier C, He J, et al
    Differential Impact of Left Ventricular Myocardium and Left Coronary Radiation Dose with Incident Heart Failure and Coronary Events in Lung Cancer Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2025 Jun 25:S0360-3016(25)04493.
    PubMed         Abstract available

  26. SAMSON P, Robinson C
    How to Avoid Collapsing Under the Pressure of Managing Atelectasis During Lung Cancer Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:785.
    PubMed        

  27. MEYER S, Hu YC, Rimner A, Mechalakos J, et al
    Deformable Image Registration Uncertainty-Encompassing Dose Accumulation for Adaptive Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:818-826.
    PubMed         Abstract available

  28. CHUONG MD, Mittauer KE, Bassetti MF, Rojas C, et al
    Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2025;122:957-967.
    PubMed         Abstract available


    J Clin Oncol

  29. STEUER CE, Hayashi H, Su WC, Nishio M, et al
    Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.
    J Clin Oncol. 2025 Jun 24:JCO2402744. doi: 10.1200/JCO-24-02744.
    PubMed         Abstract available


    J Thorac Cardiovasc Surg

  30. ZERVOS M, Park BJ, Marshall MB, Wee JO, et al
    Robotic-assisted single-port system for pulmonary lobectomy: A prospective feasibility study.
    J Thorac Cardiovasc Surg. 2025;170:54-60.
    PubMed         Abstract available


    JAMA Oncol

  31. LI H, Chen K, Gong L, Qin J, et al
    High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2025 Jun 26. doi: 10.1001/jamaoncol.2025.1779.
    PubMed         Abstract available

  32. MARKS JA, Liu SV
    Navigating Selective Dose Intensification in EGFR-Variant Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 Jun 26. doi: 10.1001/jamaoncol.2025.1768.
    PubMed        


    Lung Cancer

  33. GEORGE JE, George PS, Krishna JKM, Mathew A, et al
    Global trends in lung cancer incidence and mortality by age, gender and morphology and forecast: A bootstrap-based analysis.
    Lung Cancer. 2025;205:108626.
    PubMed         Abstract available

  34. WU Y, Xie Y, Chen Y, Li J, et al
    Bronchial washing fluid supernatant serves as a novel liquid biopsy specimen for genome profiling in advanced non-small cell lung cancer.
    Lung Cancer. 2025;205:108622.
    PubMed         Abstract available

  35. PEREZ-PEREZ M, de Sola-Llamas CG, Macias-Garcia L
    Diagnostic accuracy of the Idylla mutation test for detecting EGFR mutations in non-small cell lung cancer: a meta-analysis.
    Lung Cancer. 2025;205:108623.
    PubMed         Abstract available

  36. ZHANG M, Tang Y, Liang J, Zhu L, et al
    Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase ? study.
    Lung Cancer. 2025;205:108630.
    PubMed         Abstract available

  37. GAWLI CS, Patil BR, Nagpure NR, Patil CR, et al
    Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis.
    Lung Cancer. 2025;205:108629.
    PubMed         Abstract available

  38. MOGHANAKI D, Cameron EA, Garon EB
    Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer.
    Lung Cancer. 2025 Jun 20:108628. doi: 10.1016/j.lungcan.2025.108628.
    PubMed        

  39. SUNG H, Jiang C, Schafer EJ, Bandi P, et al
    Burden and trends in subsequent primary lung cancer incidence by sex in the United States.
    Lung Cancer. 2025;205:108625.
    PubMed         Abstract available


    Mol Carcinog

  40. GONG Z, Yu F, Li C, Zhao B, et al
    Four-gene Prognostic Signature and Risk of Brain Metastasis of Lung Adenocarcinoma.
    Mol Carcinog. 2025;64:1209-1221.
    PubMed         Abstract available

  41. LIU Z, Lenz HJ, Yu J, Zhang L, et al
    Differential Response and Resistance to KRAS-Targeted Therapy.
    Mol Carcinog. 2025;64:1135-1148.
    PubMed         Abstract available


    Oncologist

  42. ISAWA T, Togashi S, Taguri M, Toi Y, et al
    Cardiovascular adverse events in patients with lung cancer treated with immune checkpoint inhibitors: a nationwide database study.
    Oncologist. 2025;30:oyaf151.
    PubMed         Abstract available

  43. WANG W, Xu X, Liu H, Cui Y, et al
    The prognostic value of sarcopenia and sarcopenic obesity in patients with lung cancer receiving immunotherapy: a propensity score matching study.
    Oncologist. 2025;30:oyaf114.
    PubMed         Abstract available

  44. LI G, Greene SB, Kaur B, Keller-Evans RB, et al
    Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancer.
    Oncologist. 2025;30:oyaf159.
    PubMed         Abstract available


    PLoS One

  45. PUTHDEE N, Mai VH, Settayanon S, Chanvorachote P, et al
    HMGB1-BoxA gene therapy in reversing cisplatin resistance in non-small cell lung cancer.
    PLoS One. 2025;20:e0327144.
    PubMed         Abstract available

  46. RENIERS T, Noordzij PG, Veen EJ, Hofman EFN, et al
    Does postoperative plasma IL-6 improve early prediction of infection after pulmonary cancer surgery? A two-centre prospective study.
    PLoS One. 2025;20:e0326537.
    PubMed         Abstract available


    Thorax

  47. ROCHE JJ, Seyedshahi F, Rakovic K, Thu AW, et al
    Current and future applications of artificial intelligence in lung cancer and mesothelioma.
    Thorax. 2025 Jun 20:thorax-2024-222054. doi: 10.1136/thorax-2024-222054.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.